文献速递产科母胎医学

产前抗抑郁药使用与妊娠期高血压疾病风险

Prenatal antidepressant use and the implication of hypertensive disorders during pregnancy.
PubMed 文献 · Am J Obstet Gynecol · 2021-06-08

本研究基于台湾健康福利数据库的回顾性队列,纳入5664例18-49岁抑郁症孕妇,比较产前抗抑郁药暴露与妊娠期高血压疾病风险。结果显示产前抗抑郁药使用与妊娠期高血压疾病风险无关(aHR 0.89,95%CI 0.67-1.18),但高累积剂量组风险高于低累积剂量组(aHR 2.46,95%CI 1.05-5.74)。

要点

  • 产前抗抑郁药使用未增加妊娠期高血压疾病风险(aHR 0.89)。
  • 高累积剂量抗抑郁药者妊娠期高血压疾病风险较低剂量者升高(aHR 2.46)。
  • 高累积剂量抗抑郁药孕妇可能需要更频繁或定期监测血压。

核心结论

  • 产前抗抑郁药使用与妊娠期高血压疾病发生无关联。
  • 但使用较高累积剂量抗抑郁药的女性风险更高。
  • 高累积剂量抗抑郁药女性可能需要更频繁或定期监测血压。

研究设计与样本

  • 回顾性队列研究,使用台湾健康福利数据库。
  • 纳入18至49岁抑郁症孕妇共5664例,2832例抗抑郁药使用者匹配2832例非使用者。
  • 产前抗抑郁药使用定义为受孕日至妊娠20周间至少1次抗抑郁药配药记录。
  • 按累积限定日剂量分为低累积剂量组(≤70)和高累积剂量组(>70)。
  • 采用倾向评分匹配和稳定逆概率治疗加权平衡混杂因素,稳健Cox回归评估关联。

主要发现

  • 产前抗抑郁药使用与妊娠期高血压疾病风险无关(调整风险比0.89,95%CI 0.67-1.18)。
  • 抗抑郁药使用者中,高累积剂量组较低累积剂量组妊娠期高血压疾病风险更高(调整风险比2.46,95%CI 1.05-5.74)。

关键数值与推荐

  • 主要结局为妊娠20周至分娩期间诊断妊娠期高血压或子痫前期。
  • 低累积剂量组为累积限定日剂量≤70,高累积剂量组为>70。

临床怎么用

  • 产前使用抗抑郁药本身不增加妊娠期高血压疾病风险,无需因此常规干预。
  • 对使用高累积剂量抗抑郁药的孕妇,可考虑更频繁或定期监测血压。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence for the association between prenatal antidepressant use and the development of hypertensive disorders of pregnancy is inconsistent. Previous studies have reported that antidepressant use during pregnancy increases the risk for gestational hypertension and preeclampsia, but the results of these studies are potentially confounded by important methodologic limitations. Furthermore, it remains unknown whether a higher cumulative dose of antidepressant increases the risk for hypertensive disorders of pregnancy. OBJECTIVE: This study aimed to investigate the association between prenatal antidepressant use and the risk for hypertensive disorders of pregnancy and the potential effect of a higher cumulative antidepressant dose. STUDY DESIGN: This retrospective cohort study used data from the Health and Welfare Database in Taiwan. Pregnant women with depression aged 18 to 49 years were enrolled as part of the study population. Prenatal antidepressant use was defined as at least 1 dispensing record of an antidepressant between the conception date and 20 weeks of gestation. Antidepressant users were further divided into groups according to the cumulative defined daily dose based on whether they took the defined daily dose for ≤10 weeks (low cumulative dose group ≤70 cumulative defined daily dose) or for >10 weeks (high cumulative dose group >70 cumulative defined daily dose). The primary outcome was hypertensive disorders of pregnancy defined as the diagnosis of either gestational hypertension or preeclampsia during the period from 20 weeks of gestation to delivery. Propensity score matching and stabilized inverse probability of treatment weighting were used to balance the confounders between the comparison groups. A robust Cox regression model was used to evaluate the association between exposure and outcome. RESULTS: A total of 5664 pregnant women with depression were included in the study (2832 antidepressant users matched to 2832 antidepressant nonusers). Prenatal antidepressant use was not associated with an increased risk for hypertensive disorders of pregnancy (adjusted hazard ratio, 0.89; 95% confidence interval, 0.67-1.18). However, among antidepressant users, the risk for hypertensive disorders of pregnancy was higher among women with a higher cumulative defined daily dose than among women with a lower cumulative defined daily dose (adjusted hazard ratio, 2.46; 95% confidence interval, 1.05-5.74). CONCLUSION: No association was found between antidepressant use and the development of hypertensive disorders of pregnancy. However, women taking higher cumulative doses of antidepressants were at greater risk. More frequent or regular monitoring of blood pressure may be warranted in women on high cumulative doses of antidepressants.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Yang LY, Lin FJ, Katz AJ, et al. Prenatal antidepressant use and the implication of hypertensive disorders during pregnancy. Am J Obstet Gynecol. 2021. PMID: 34116038. doi:10.1016/j.ajog.2021.06.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。